Aravive, Inc.: Nasdaq/NYSE listing notice — Aravive fails to meet three Nasdaq listing standards; cure period to March 13, 2024

Aravive, Inc.

MVLS below $50M for 30 consecutive business days (Aug 3-Sep 14, 2023); 180-day cure ends March 13, 2024.
MVPHS below $15M over same period; compliance requires closing at $15M+ for 10 consecutive days.
Minimum bid price below $1.00 for 30 consecutive days; same cure period applies.
If not cured by March 13, 2024, Nasdaq may delist; company can appeal or apply to transfer to Nasdaq Capital Market.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aravive, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A), 5450(b)(2)(C)

Exact text from the filing

ifying the Company that for the preceding 30 consecutive business days (August 3, 2023 through September 14, 2023), the market value of the Company’s listed securities (“MVLS”) did not maintain a minimum market value of $50,000,000 (the “Minimum MVLS Requirement”) as required by Nasdaq Listing Rule 5450(b)(2)(A). The notification received has no immediate effect on the Company's continued listing on the Nasdaq Global Market, subject to the Company's compliance with the other continued listing requirements. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance perio

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001437749-23-026308

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.